SAB Biotherapeutics Inc Ordinary Shares SABS 深 沪
交易中 04-01 11:20:25 美东时间
3.88
+0.050
+1.31%
华盛通- 最 高3.93
- 今 开3.84
- 成交量 9.93万股
- 最 低 3.84
- 昨 收 3.83
- 总市值 2.73亿
- 52周最高 6.60
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 1.23
- 委 比 -14.29%
- 总股本 7027.57万
- 历史最高 129.00
- 量 比 0.65
- 振 幅 2.35%
- 历史最低 1.00
- 每 手 1
- 风险率 0.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SAB Biotherapeutics Launches Public Stock Offering To Fund Development Of Type 1 Diabetes Therapy; No Terms Disclosed
SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
03-18 04:03
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
SAB Biotherapeutics Announces Additional Data From Phase 1 HUman Anti-Thymocyte Biologic In First-In-MAN Clinical Trial Of SAB-142; Results Demonstrated Early Signals Of C-peptide Preservation
T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 dataMIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage
03-10 19:35
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.
01-08 04:28
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in
2025-12-17 21:05
SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
2025-12-08 21:11
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
2025-11-17 20:13
